Registration of Multisensor Images through a Conditional Generative Adversarial Network and a Correlation-Type Similarity Measure

The automatic registration of multisensor remote sensing images is a highly challenging task due to the inherently different physical, statistical, and textural characteristics of the input data. Information-theoretic measures are often used to favor comparing local intensity distributions in the images. In this paper, a novel method based on the combination of a deep learning architecture and a correlation-type area-based functional is proposed for the registration of a multisensor pair of images, including an optical image and a synthetic aperture radar (SAR) image. The method makes use of a conditional generative adversarial network (cGAN) in order to address image-to-image translation across the optical and SAR data sources. Then, once the optical and SAR data are brought to a common domain, an area-based ℓ2 similarity measure is used together with the COBYLA constrained maximization algorithm for registration purposes. While correlation-type functionals are usually ineffective in the application to multisensor registration, exploiting the image-to-image translation capabilities of cGAN architectures allows moving the complexity of the comparison to the domain adaptation step, thus enabling the use of a simple ℓ2 similarity measure, favoring high computational efficiency, and opening the possibility to process a large amount of data at runtime. Experiments with multispectral and panchromatic optical data combined with SAR images suggest the effectiveness of this strategy and the capability of the proposed method to achieve more accurate registration as compared to state-of-the-art approaches

Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: different effects in different patients populations. Results from a large observational study

Tenofovir alafenamide (TAF) has similar efficacy compared to tenofovir disoproxil fumarate (TDF), but a less favorable effect on lipids. Aim of this study was to evaluate the impact on lipids of switching from rilpivirine (RPV)/ emtricitabine (FTC)/TDF to RPV/FTC/TAF in a large cohort of HIV-1 infected patients

Calibration Optimization Methodology for Lithium-Ion Battery Pack Model for Electric Vehicles in Mining Applications

Large-scale introduction of electric vehicles (EVs) to the market sets outstanding requirements for battery performance to extend vehicle driving range, prolong battery service life, and reduce battery costs. There is a growing need to accurately and robustly model the performance of both individual cells and their aggregated behavior when integrated into battery packs. This paper presents a novel methodology for Lithium-ion (Li-ion) battery pack simulations under actual operating conditions of an electric mining vehicle. The validated electrochemical-thermal models of Li-ion battery cells are scaled up into battery modules to emulate cell-to-cell variations within the battery pack while considering the random variability of battery cells, as well as electrical topology and thermal management of the pack. The performance of the battery pack model is evaluated using transient experimental data for the pack operating conditions within the mining environment. The simulation results show that the relative root mean square error for the voltage prediction is 0.7–1.7% and for the battery pack temperature 2–12%. The proposed methodology is general and it can be applied to other battery chemistries and electric vehicle types to perform multi-objective optimization to predict the performance of large battery packs

Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/ emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia

open10noTenofovir alafenamide (TAF) has similar efficacy compared to tenofovir disoproxil fumarate (TDF), but a less favorable effect on lipids. Aim of this retrospective multicentre study was to evaluate the impact on lipids of switching from rilpivirine (RPV)/ emtricitabine (FTC)/TDF to RPV/FTC/TAF in a cohort of HIV-1 infected patients. Total cholesterol (TC), high density lipoproteins (HDL) and low density lipoproteins (LDL) were compared at the moment of the switch and at the first following evaluation, by using paired t-test. Overall, 573 patients were considered, 99% with HIV-RNA <50 copies/ml, with mean age of 49.7 (±0.4) years and median 13.4 (6.9-22.5) years of HIV infection. In the study population with available data (431/573, 75%), mean TC changed from 173 ±1.7 to 188 ±1.8 mg/dl; mean HDL from 46 ±0.7 to 51± 0.7 mg/dl; mean LDL from 111 ±1.5 to 120 ±1.8 mg/dl (p<0.0001 for all). Neither LDL/HDL nor TC/HDL ratio changed significantly, with LDL/HDL from 2.6 ±0.5 to 2.5 ±0.5 (p = 0.12) and TC/HDL from 4.0 ±0.6 to 3.9 ±0.6 (p = 0.11). In patients with baseline diagnosis of hypercholesterolemia (TC>200 mg/dl, N = 87), there was no significant change in TC (224 ±2.2 to 228 ±3.4 mg/dl, p = 0.286) or LDL (150±2.5 to 151±3.2 mg/dl, p = 0.751), while HDL increased from 51 ±1.6 to 55 ±1.7 mg/dl (p<0.0001) and both LDL/HDL and TC/HDL ratio decreased significantly, from 3.2±0.1 to 3.0 ±0.1 (p = 0.025) and from 4.7±0.1 to 4.4 ±0.1 (p = 0.004). In this real life study, a slight increase in lipids was found after switching from RPV/FTC/TDF to RPV/FTC/TAF, but these results were not confirmed in people with hypercholesterolemia, in which lipids did not change and LDL/HDL and TC/HDL ratio decreased.openTaramasso L.; Di Biagio A.; Riccardi N.; Briano F.; Di Filippo E.; Comi L.; Mora S.; Giacomini M.; Gori A.; Maggiolo F.Taramasso, L.; Di Biagio, A.; Riccardi, N.; Briano, F.; Di Filippo, E.; Comi, L.; Mora, S.; Giacomini, M.; Gori, A.; Maggiolo, F

Dasabuvir and Ombitasvir/Paritaprevir/Ritonavir with or without Ribavirin in Patients with HIV-HCV Coinfection. Real Life Interim Analysis of an Italian Multicentre Compassionate Use Program

Background and Aims: An HCV cure is now possible in a large proportion of HIV-HCV patient. We present real life results of a compassionate use program promoted by SIMIT (Infectious and Tropical Diseases Italian Society) of Dasabuvir and Ombitasvir/Paritaprevir/Ritonavir ± Ribavirin for 12 weeks in 213 HIV-HCV genotype 1 patients. Data on efficacy and tolerability of this strategy in HIV patients have been reported until now only in 43 non cirrhotic HIV subjects

Evaluating LoRaWAN connectivity in a marine scenario

The growing need for interoperability among the different oceanic monitoring systems to deliver services able to answer the requirements of stakeholders and end-users led to the development of a low-cost machine-to-machine communication system able to guarantee data reliability over marine paths. In this framework, an experimental evaluation of the performance of long-range (LoRa) technology in a fully operational marine scenario has been proposed. In-situ tests were carried out exploiting the availability of (i) a passenger vessel and (ii) a research vessel operating in the Ligurian basin (North-Western Mediterranean Sea) both hosting end-nodes, and (iii) gateways positioned on mountains and hills in the inland areas. Packet loss ratio, packet reception rate, received signal strength indicator, signal to noise, and expected signal power ratio were chosen as metrics in line of sight and not the line of sight conditions. The reliability of Long Range Wide Area Network (LoRaWAN) transmission over the sea has been demonstrated up to more than 110 km in a free space scenario and for more than 20 km in a coastal urban environment

Modelling the Dynamics of an Aedes albopictus Population

We present a methodology for modelling population dynamics with formal means of computer science. This allows unambiguous description of systems and application of analysis tools such as simulators and model checkers. In particular, the dynamics of a population of Aedes albopictus (a species of mosquito) and its modelling with the Stochastic Calculus of Looping Sequences (Stochastic CLS) are considered. The use of Stochastic CLS to model population dynamics requires an extension which allows environmental events (such as changes in the temperature and rainfalls) to be taken into account. A simulator for the constructed model is developed via translation into the specification language Maude, and used to compare the dynamics obtained from the model with real data.Comment: In Proceedings AMCA-POP 2010, arXiv:1008.314

No impact of previous NRTIs resistance in HIV positive patients switched to DTG+2NRTIs under virological control: Time of viral suppression makes the difference

The accumulation of drug-resistance mutations on combined antiretroviral regimens (ART) backbone could affect the virological efficacy of the regimen. Our aim was to assess the impact of previous drug resistance to nucleoside reverse transcriptase inhibitors (NRTIs) on the probability of virological failure (VF) in patients, under virological control, who switched to dolutegravir (DTG)+2NRTIs regimens. All HIV-1 positive drug-experienced patients who started a regimen composed by DTG+2NRTIs [abacavir/lamivudine or tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF)/emtricitabine (FTC)] in the ARCA collaborative group with HIV-RNA <50 cp/mL were included in the analysis. Patients with a previous VF to integrase inhibitors were excluded. The impact of single and combined NRTIs mutations on the probability of VF (defined as 2 consecutive HIV-RNA >50 copies/mL or one HIV-RNA >1000 copies/mL) was assessed by Kaplan Meier curves. A multivariable Cox regression analysis was constructed to assess factors potentially related to VF. Five hundred and eighty-eight patients were included in the analysis with a median time of viral suppression before the switch of 37 months (IQR 12-78), of whom 148 (25.2%) had at least one previous NRTIs resistance mutation. In the multivariable model no association was observed between NRTIs mutations and VF. Conversely, the duration of viral suppression before switch resulted associated with a lower risk of VF (for 1 month increase, adjusted 0.98, 95%CI 0.96-0.99; p=0.024). Previous NRTIs mutations appeared to have no impact on the risk of VF in patients switched to DTG+2NRTIs, whereas a longer interval on a controlled viremia decreased significantly the risk of VF